

Sucampo Pharmaceuticals, Inc.  
Form SC 13G/A  
February 13, 2018

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

SCHEDULE 13G

(Rule 13d-102)  
(Amendment No. 1)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO  
FILED PURSUANT TO RULE 13d-2

Sucampo Pharmaceuticals, Inc.

---

(Name of Issuer)

Class A Common Stock

---

(Title of Class of Securities)

864909106

---

(CUSIP Number)

December 31, 2017

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)  
Rule 13d-1(c)  
Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---



NAME OF REPORTING PERSON

1

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

ING Groep N.V.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

2

(a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

The Netherlands

SOLE VOTING POWER

5

0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

SHARED VOTING POWER

6

0

SOLE DISPOSITIVE POWER

7

0

SHARED DISPOSITIVE POWER

8

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9

0

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

10

PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW (9)

11

0% (1)

TYPE OF REPORTING PERSON  
(See Instructions)

12

HC

---

(1) Based on 46,636,924 shares of Class A Common Stock issued and outstanding as of October 26, 2017, as reported by the issuer in its Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 1, 2017.

---

NAME OF REPORTING PERSON

1

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

ING Bank N.V.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a)

(b)

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

The Netherlands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

SOLE VOTING POWER

5  
0

SHARED VOTING POWER

6  
0

SOLE DISPOSITIVE POWER

7  
0

SHARED DISPOSITIVE POWER

8  
0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

11 PERCENT OF CLASS  
REPRESENTED BY AMOUNT IN  
ROW (9)

0 (1)

12 TYPE OF REPORTING PERSON  
(See Instructions)

CO

---

This Amendment No. 1 (this "Amendment") to Schedule 13G amends the Schedule 13G filed on December 14, 2017 (the "Schedule 13G") by (i) ING Groep N.V. and (ii) ING Bank N.V. (together, the "Reporting Persons") with respect to the Class A Common Stock of Sucampo Pharmaceuticals, Inc. Capitalized terms used but not defined herein shall have the meaning set forth in the Schedule 13G. The filing of this Amendment represents the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons.

---

- Item 1(a). Name of Issuer:  
Sucampo Pharmaceuticals, Inc.
- Item 1(b). Address of Issuer's Principal Executive Offices:  
805 King Farm Boulevard, Suite 550  
Rockville, MD 20850
- Item 2(a). Name of Person Filing:  
ING Groep N.V.  
ING Bank N.V.
- Item 2(b). Address of Principal Business Office or, if none, Residence:  
ING Groep N.V.  
Bijlmerplein 888  
1102 MG  
Amsterdam-Zuidoost  
Postbus 1800  
1000 BV Amsterdam  
The Netherlands  
  
ING Bank N.V.  
Bijlmerplein 888  
1102 MG  
Amsterdam-Zuidoost  
Postbus 1800  
1000 BV Amsterdam  
The Netherlands
- Item 2(c). Citizenship:  
ING Groep N.V. – The Netherlands  
ING Bank N.V. – The Netherlands
- Item 2(d). Title of Class of Securities:  
Class A Common Stock
- Item 2(e). CUSIP Number:  
864909106
- Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), 13d-2(b) or (c), Check Whether the Person Filing is a:  
(a) Broker or dealer registered under Section 15 of the Exchange Act.  
(b) Bank as defined in Section 3(a)(6) of the Exchange Act.  
(c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.  
(d) Investment company as defined under Section 8 of the Investment Company Act.  
(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Edgar Filing: Sucampo Pharmaceuticals, Inc. - Form SC 13G/A

- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  - (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  - (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
  - (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
  - (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).
- Not Applicable
-



Item  
4. Ownership:

- (a) ING Groep N.V. and ING Bank N.V. each may be deemed to be the beneficial owner of 0 shares of Class A Common Stock.  
ING Groep N.V. and ING Bank N.V., a direct wholly-owned subsidiary of ING Groep N.V., may be deemed to be the beneficial owner of 0% of Class A Common Stock based on 46,636,924 shares of Class A Common Stock issued and outstanding as of October 26, 2017, as reported by the issuer in its Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 1, 2017.
- (b) Neither ING Groep N.V. nor ING Bank N.V. has sole or shared power to vote or direct the disposition of any shares of Class A Common Stock.
- (c)

Item  
5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

This final amendment reflects that each Reporting Person has ceased to be the beneficial owner of more than five percent of the Class A Common Stock of the issuer.

Item  
6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item  
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable.

Item  
8. Identification and Classification of Members of the Group.

Not Applicable.

Item  
9. Notice of Dissolution of Group.

Not Applicable.

Item  
10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2018

ING GROEP N.V.

By: /s/ F. Severin  
Name: F. Severin  
Title: Compliance Officer

By: /s/ J.A.M. Emke-Petrelluzzi Bojanic  
Name: J.A.M. Emke-Petrelluzzi Bojanic  
Title: Senior Compliance Officer

ING BANK N.V.

By: /s/ F. Severin  
Name: F. Severin  
Title: Compliance Officer

By: /s/ J.A.M. Emke-Petrelluzzi Bojanic  
Name: J.A.M. Emke-Petrelluzzi Bojanic  
Title: Senior Compliance Officer

---

Exhibit A to Schedule 13G  
Joint Filing Agreement  
Pursuant to Rule 13d-1(k)

The undersigned persons (the "Reporting Persons") hereby agree that a joint statement on this Amendment No. 1 to Schedule 13G be filed on their behalf by ING Groep N.V.

Each of the Reporting Persons is responsible for the completeness and accuracy of the information concerning each of them contained therein, but none of the Reporting Persons is responsible for the completeness or accuracy of the information concerning any other Reporting Person.

Dated: February 13, 2018

ING GROEP N.V.

By: /s/ F. Severin  
Name: F. Severin  
Title: Compliance Officer

By: /s/ J.A.M. Emke-Petrelluzzi Bojanic  
Name: J.A.M. Emke-Petrelluzzi Bojanic  
Title: Senior Compliance Officer

ING BANK N.V.

By: /s/ F. Severin  
Name: F. Severin  
Title: Compliance Officer

By: /s/ J.A.M. Emke-Petrelluzzi Bojanic  
Name: J.A.M. Emke-Petrelluzzi Bojanic  
Title: Senior Compliance Officer

---